Leadership
Our Team
A wide range of expertise with a singular focus.
We are a team of specialists with extensive experience working with and supporting patient communities, driven by our mission to bring new therapeutic options to people living with rare diseases. Individually, we bring varied expertise and backgrounds to our work. Collectively, we are guided by our values – they shape who we are, how we rise to challenges, and keep us grounded in our focus.
Matt Trudeau
President, ITF Therapeutics
Matt Trudeau
President, ITF Therapeutics
Matt Trudeau has dedicated his career to bringing innovative life-changing therapies to patients in need around the world. He has more than 25 years of experience leading the development and execution of commercialization strategies for biotechnology products in a range of therapeutic areas including rare diseases, oncology, and neurology. Matt has made his impact by leading mission-focused teams at Genzyme, Biogen, and bluebird bio. He earned his BA in biochemistry at Colby College and his MS in molecular biology at Northeastern University.
Erica L. Monaco, CPA
Chief Operating Officer
Erica L. Monaco, CPA
Chief Operating Officer
Stephanie Trafton
Head of US Value & Access
Stephanie Trafton
Head of US Value & Access